60 Degrees Pharmaceuticals (SXTP) Accounts Payables (2022 - 2026)
60 Degrees Pharmaceuticals (SXTP) posted quarterly Accounts Payables of $1.5 million for Q1 2026, up 28.46% year-over-year from $1.2 million in Q1 2025, and up 1.94% quarter-over-quarter from $1.5 million in Q4 2025.
60 Degrees Pharmaceuticals (SXTP) Accounts Payables (2022 - 2026) Analysis & Trends
60 Degrees Pharmaceuticals (SXTP) has reported Accounts Payables for 5 consecutive years, with $1.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accounts Payables rose 28.46% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $1.5 million (up 28.46% YoY), while the FY2025 annual figure was $1.5 million, up 44.82% from the prior year.
- Accounts Payables rose to $1.5 million in Q1 2026 per SXTP's latest filing, from $1.5 million in the prior quarter.
- Across five years, Accounts Payables topped out at $1.5 million in Q1 2026 and bottomed at $271602.0 in Q3 2023.
- Historically, Accounts Payables has averaged $911912.6 across 5 years, with a median of $905813.0 in 2025.
- On a YoY basis, Accounts Payables climbed as much as 149.49% in 2024 and fell as far as 39.21% in 2024.
- 60 Degrees Pharmaceuticals' Accounts Payables stood at $758668.0 in 2022, then plunged by 33.28% to $506206.0 in 2023, then surged by 99.05% to $1.0 million in 2024, then jumped by 44.82% to $1.5 million in 2025, then climbed by 1.94% to $1.5 million in 2026.
- Business Quant data shows SXTP's Accounts Payables at $1.5 million in Q1 2026, $1.5 million in Q4 2025, and $1.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | 60 Degrees Pharmaceuticals | 3.00 Mn | 1.98 Mn | 56,798.00 | 1.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.49 Mn |
| Dec 31, 2025 | 1.46 Mn |
| Sep 30, 2025 | 1.39 Mn |
| Jun 30, 2025 | 905,813.00 |
| Mar 31, 2025 | 1.16 Mn |
| Dec 31, 2024 | 1.01 Mn |
| Sep 30, 2024 | 677,617.00 |
| Jun 30, 2024 | 643,375.00 |
| Mar 31, 2024 | 529,449.00 |
| Dec 31, 2023 | 506,206.00 |
| Sep 30, 2023 | 271,602.00 |
| Jun 30, 2023 | 1.06 Mn |
| Dec 31, 2022 | 758,668.00 |